What to Know About BinaxNow Shortages


This Alert is outdated. Please visit our Alerts page for the latest updates and information.


As you may have seen in the news, one of our testing vendors, Abbott Laboratories, scaled down production of their BinaxNow rapid antigen test earlier this year as COVID-19 transmission rates started to decline. This has led to a significant supply gap for this type of test nationwide as demand once again skyrockets amid surging transmission rates. Abbott is working to reestablish manufacturing to previous levels to meet this demand, but these supply chain constraints are already being felt by testing providers across the country.

Health Commons Project (HCP) is working very closely with the Washington State Department of Health (DOH) to mitigate the impact of these shortages on L2R districts and reestablish a dependable pipeline of rapid antigen tests for the 2021-2022 school year.

Here’s what you need to know as an L2R district:

  • There is no need to modify your testing models to maintain a stockpile of inventory; we will work to find a supply chain that meets your demand.


  • We are working to diversify our supply chain of rapid antigen tests with other, DOH-approved vendors to secure inventory for the coming months.
  • We will continue working with Abbott once they have reestablished their supply pipeline.


  • This shortage does not affect schools using a swab-and-send model (i.e., Curative or pooled testing) for diagnostic testing.

We will keep you informed of changes as they occur, and help you prepare for onboarding of new testing vendors as needed, including updating consent and reporting procedures.


Thank you for your continued leadership as an L2R district!